tiprankstipranks
VYNE Therapeutics announces dosing of first subject in Phase 2b trial of VYN201
PremiumThe FlyVYNE Therapeutics announces dosing of first subject in Phase 2b trial of VYN201
2M ago
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
PremiumPress Releases
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
2M ago
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
PremiumPress Releases
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
2M ago
Vyne Therapeutics Inc’s New Natural and Human Disruptions Risk – A Cause for Worry?
PremiumCompany AnnouncementsVyne Therapeutics Inc’s New Natural and Human Disruptions Risk – A Cause for Worry?
5M ago
VYNE Therapeutics files $250M mixed securities shelf
PremiumThe Fly
VYNE Therapeutics files $250M mixed securities shelf
5M ago
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
PremiumPress Releases
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
5M ago
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
PremiumPress ReleasesVYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
6M ago
VYNE Therapeutics announces biomarker data from Phase 1b trial of VYN201
PremiumThe Fly
VYNE Therapeutics announces biomarker data from Phase 1b trial of VYN201
6M ago
VYNE Therapeutics appoints Borowski to board of directors
PremiumThe Fly
VYNE Therapeutics appoints Borowski to board of directors
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100